{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:55Z","timestamp":1792801675121,"version":"4.5.0"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cholinesterase inhibitors are commonly used to treat patients with neurocognitive disorders, who often have an elevated risk of falling. Effective use of these medications requires a thoughtful assessment of risks and benefits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To provide an update on previous reviews and determine the association between cholinesterase inhibitors and falls, syncope, fracture and accidental injuries in patients with neurocognitive disorders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Embase, MEDLINE, Cochrane Central Register of Controlled Trials, Cumulative Index of Nursing and Allied Health Literature and AgeLine were systematically searched through March 2023 to identify all randomised controlled trials of cholinesterase inhibitors (donepezil, galantamine, rivastigmine) in patients with cognitive impairment. Corresponding authors were contacted for additional data necessary for meta-analysis. Inclusion criteria consisted of adults \u226519\u00a0years, with a diagnosis of dementia, Parkinson\u2019s disease, mild cognitive impairment or traumatic brain injury. Data were extracted in duplicate for the aforementioned primary outcomes and all outcomes were analysed using random-effects meta-analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty three studies (30 donepezil, 14 galantamine, 9 rivastigmine) were included providing data on 25, 399 patients. Cholinesterase inhibitors, compared to placebo, were associated with reduced risk of falls (risk ratio [RR] 0.84 [95% confidence interval [CI]\u2009=\u20090.73\u20130.96, P\u2009=\u20090.009]) and increased risk of syncope (RR 1.50 [95% CI\u2009=\u20091.02\u20132.21, P\u2009=\u20090.04]). There was no association with accidental injuries or fractures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with neurocognitive disorders, cholinesterase inhibitors were associated with decreased risk of falls, increased risk of syncope and no association with accidental trauma or fractures. These findings will help clinicians better evaluate risks and benefits of cholinesterase inhibitors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ageing\/afad205","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T03:33:14Z","timestamp":1700710394000},"source":"Crossref","is-referenced-by-count":13,"title":["Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"52","author":[{"given":"Manan","family":"Ahuja","sequence":"first","affiliation":[{"name":"McMaster University Department of Medicine, , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailee","family":"Siddhpuria","sequence":"additional","affiliation":[{"name":"University of Toronto Department of Family and Community Medicine, , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Karimi","sequence":"additional","affiliation":[{"name":"University of Illinois College of Medicine Department of Medicine, , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Lewis","sequence":"additional","affiliation":[{"name":"McMaster University Department of Medicine, , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1759-8603","authenticated-orcid":false,"given":"Eric","family":"Wong","sequence":"additional","affiliation":[{"name":"University of Toronto Division of Geriatric Medicine, Department of Medicine, , Toronto , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lee","sequence":"additional","affiliation":[{"name":"McMaster University Division of Geriatric Medicine, Department of Medicine, , Hamilton , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-3185","authenticated-orcid":false,"given":"Christina","family":"Reppas-Rindlisbacher","sequence":"additional","affiliation":[{"name":"University of Toronto Division of Geriatric Medicine, Department of Medicine, , Toronto , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Sood","sequence":"additional","affiliation":[{"name":"McMaster University Faculty of Science, Department of Psychology, Neuroscience & Behaviour, , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gabor","sequence":"additional","affiliation":[{"name":"Hamilton Health Sciences , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Patterson","sequence":"additional","affiliation":[{"name":"McMaster University Division of Geriatric Medicine, Department of Medicine, , Hamilton , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"2023112303242872800_ref1"},{"key":"2023112303242872800_ref2"},{"key":"2023112303242872800_ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/906274","article-title":"Recurrent falls in Parkinson\u2019s disease: a systematic review","volume":"2013","author":"Allen","year":"2013","journal-title":"Parkinsons Dis"},{"key":"2023112303242872800_ref4","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.2522\/ptj.20080117","article-title":"Mild cognitive impairment increases falls risk in older community-dwelling women","volume":"88","author":"Liu-Ambrose","year":"2008","journal-title":"Phys Ther"},{"key":"2023112303242872800_ref5","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1017\/S1041610216001113","article-title":"Influence of cognitive impairment on fall risk among elderly nursing home residents","volume":"28","author":"Seijo-Martinez","year":"2016","journal-title":"Int Psychogeriatr"},{"key":"2023112303242872800_ref6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jagp.2017.09.027","article-title":"A systematic review of practice guidelines and recommendations for discontinuation of cholinesterase inhibitors in dementia","volume":"26","author":"Renn","year":"2018","journal-title":"Am J Geriatr Psychiatry"},{"key":"2023112303242872800_ref7","doi-asserted-by":"crossref","first-page":"e0144337","DOI":"10.1371\/journal.pone.0144337","article-title":"Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada","volume":"10","author":"Ali","year":"2015","journal-title":"PloS One"},{"key":"2023112303242872800_ref8","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/alz.12105","article-title":"Recommendations of the 5th Canadian consensus conference on the diagnosis and treatment of dementia","volume":"16","author":"Ismail","year":"2020","journal-title":"Alzheimers Dement"},{"key":"2023112303242872800_ref9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e3181f6128c","article-title":"Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease (podcast)(e\u2013pub ahead of print)(LOE classification)","volume":"75","author":"Chung","year":"2010","journal-title":"Neurology"},{"key":"2023112303242872800_ref10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","article-title":"Rivastigmine for gait stability in patients with Parkinson\u2019s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Henderson","year":"2016","journal-title":"Lancet Neurol"},{"key":"2023112303242872800_ref11","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1532-5415.2011.03450.x","article-title":"Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials","volume":"59","author":"Kim","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"2023112303242872800_ref12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40266-015-0266-9","article-title":"A risk-benefit assessment of dementia medications: systematic review of the evidence","volume":"32","author":"Buckley","year":"2015","journal-title":"Drugs Aging"},{"key":"2023112303242872800_ref13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3233\/JAD-190546","article-title":"Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment:a systematic review and meta-analysis","volume":"71","author":"Matsunaga","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"2023112303242872800_ref14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","article-title":"Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study","volume":"169","author":"Gill","year":"2009","journal-title":"Arch Intern Med"},{"key":"2023112303242872800_ref15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2165\/00002512-200522080-00005","article-title":"Causes of syncope in patients with Alzheimer\u2019s disease treated with donepezil","volume":"22","author":"Bordier","year":"2005","journal-title":"Drugs Aging"},{"key":"2023112303242872800_ref16","doi-asserted-by":"crossref","first-page":"n1925","DOI":"10.1136\/bmj.n1925","article-title":"Use of antipsychotic drugs and cholinesterase inhibitors and risk of falls and fractures: self-controlled case series","volume":"374","author":"Wang","year":"2021","journal-title":"BMJ"},{"key":"2023112303242872800_ref17","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/jgs.15415","article-title":"Cardiovascular outcomes of cholinesterase inhibitors in individuals with dementia: a meta-analysis and systematic review","volume":"66","author":"Isik","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"2023112303242872800_ref18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1532-5415.2011.03317.x","article-title":"Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study","volume":"59","author":"Gangavati","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"2023112303242872800_ref19","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/pds.2176","article-title":"Risk of falls associated with antihypertensive medication: self-controlled case series","volume":"20","author":"Gribbin","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023112303242872800_ref20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"2023112303242872800_ref21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"2023112303242872800_ref22"},{"key":"2023112303242872800_ref23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2288-1-7","article-title":"Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials","volume":"1","author":"Derry","year":"2001","journal-title":"BMC Med Res Methodol"},{"key":"2023112303242872800_ref24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2023112303242872800_ref25","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"2023112303242872800_ref26","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023112303242872800_ref27","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2023112303242872800_ref28"},{"key":"2023112303242872800_ref29","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","article-title":"Efficacy and tolerability of donepezil in vascular dementia","volume":"34","author":"Black","year":"2003","journal-title":"Stroke"},{"key":"2023112303242872800_ref30","doi-asserted-by":"crossref","first-page":"P604","DOI":"10.1016\/j.jalz.2012.05.2099","article-title":"P3-425: safety, tolerability and efficacy of lecozotan SR in patients with mild-to-moderate Alzheimer\u2019s disease used as monotherapy or adjunctively with a cholinesterase inhibitor","volume":"8","author":"Booth","year":"2012","journal-title":"Alzheimers Dement"},{"key":"2023112303242872800_ref31","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","article-title":"Effect of donepezil on motor and cognitive function in Huntington disease","volume":"67","author":"Cubo","year":"2006","journal-title":"Neurology"},{"key":"2023112303242872800_ref32","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jagp.2018.05.008","article-title":"Donepezil treatment in patients with depression and cognitive impairment on stable antidepressant treatment: a randomized controlled trial","volume":"26","author":"Devanand","year":"2018","journal-title":"Am J Geriatr Psychiatry"},{"key":"2023112303242872800_ref33","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/01.wnl.0000344650.95823.03","article-title":"Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial","volume":"72","author":"Doody","year":"2009","journal-title":"Neurology"},{"key":"2023112303242872800_ref34","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/mds.25098","article-title":"Donepezil in Parkinson\u2019s disease dementia: a randomized, double-blind efficacy and safety study","volume":"27","author":"Dubois","year":"2012","journal-title":"Mov Disord"},{"key":"2023112303242872800_ref35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/WNL.57.4.613","article-title":"A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer\u2019s disease","volume":"57","author":"Feldman","year":"2001","journal-title":"Neurology"},{"key":"2023112303242872800_ref36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13195-016-0210-1","article-title":"ABT-126 monotherapy in mild-to-moderate Alzheimer\u2019s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension","volume":"8","author":"Gault","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"2023112303242872800_ref37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.trci.2015.06.001","article-title":"A phase 2 randomized, controlled trial of the \u03b17 agonist ABT-126 in mild-to-moderate Alzheimer\u2019s dementia","volume":"1","author":"Gault","year":"2015","journal-title":"Alzheimers Dement"},{"key":"2023112303242872800_ref38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1185\/030079902125001029","article-title":"Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer\u2019s disease","volume":"18","author":"Gauthier","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"2023112303242872800_ref39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2019s disease: results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2023112303242872800_ref40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archneur.57.1.94","article-title":"Donepezil therapy in clinical practice: a randomized crossover study","volume":"57","author":"Greenberg","year":"2000","journal-title":"Arch Neurol"},{"key":"2023112303242872800_ref41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000122961","article-title":"Donepezil treatment of patients with severe Alzheimer\u2019s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial","volume":"25","author":"Homma","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2023112303242872800_ref42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000017259","article-title":"Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer\u2019s disease","volume":"11","author":"Homma","year":"2000","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2023112303242872800_ref43","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa066583","article-title":"Donepezil for the treatment of agitation in Alzheimer\u2019s disease","volume":"357","author":"Howard","year":"2007","journal-title":"N Engl J Med"},{"key":"2023112303242872800_ref44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial","volume":"7","author":"Ikeda","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"2023112303242872800_ref45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.trci.2015.04.001","article-title":"Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer\u2019s disease","volume":"1","author":"Maher-Edwards","year":"2015","journal-title":"Alzheimers Dement"},{"key":"2023112303242872800_ref46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.57.3.481","article-title":"A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients","volume":"57","author":"Mohs","year":"2001","journal-title":"Neurology"},{"key":"2023112303242872800_ref47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/ene.13872","article-title":"Donepezil for gait and falls in mild cognitive impairment: a randomized controlled trial","volume":"26","author":"Montero-Odasso","year":"2019","journal-title":"Eur J Neurol"},{"key":"2023112303242872800_ref48"},{"key":"2023112303242872800_ref49","author":"Eisai Co., Ltd"},{"key":"2023112303242872800_ref50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"2023112303242872800_ref51","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","article-title":"Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study","volume":"158","author":"Rogers","year":"1998","journal-title":"Arch Intern Med"},{"key":"2023112303242872800_ref52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000106895","article-title":"The efficacy and safety of donepezil in patients with Alzheimer\u2019s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial","volume":"7","author":"Rogers","year":"1996","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2023112303242872800_ref53","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/STROKEAHA.109.570077","article-title":"Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia","volume":"41","author":"Rom\u00e1n","year":"2010","journal-title":"Stroke"},{"key":"2023112303242872800_ref54","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/jnnp-2018-318107","article-title":"Early use of donepezil against psychosis and cognitive decline in Parkinson\u2019s disease: a randomised controlled trial for 2 years","volume":"89","author":"Sawada","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023112303242872800_ref55","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","article-title":"Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial","volume":"61","author":"Seltzer","year":"2004","journal-title":"Arch Neurol"},{"key":"2023112303242872800_ref56","first-page":"1590","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer\u2019s disease in the nursing home setting","volume":"49","author":"Tariot","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"2023112303242872800_ref57","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/01.WNL.0000078943.50032.FC","article-title":"Donepezil in vascular dementia: a randomized, placebo-controlled study","volume":"61","author":"Wilkinson","year":"2003","journal-title":"Neurology"},{"key":"2023112303242872800_ref58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","article-title":"A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD","volume":"57","author":"Winblad","year":"2001","journal-title":"Neurology"},{"key":"2023112303242872800_ref59","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","article-title":"Donepezil in patients with severe Alzheimer\u2019s disease: double-blind, parallel-group, placebo-controlled study","volume":"367","author":"Winblad","year":"2006","journal-title":"Lancet"},{"key":"2023112303242872800_ref60","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/01.wnl.0000266625.31615.f6","article-title":"Galantamine treatment of vascular dementia: a randomized trial","volume":"69","author":"Auchus","year":"2007","journal-title":"Neurology"},{"key":"2023112303242872800_ref61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000086613","article-title":"Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer\u2019s disease","volume":"20","author":"Brodaty","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2023112303242872800_ref62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000074140","article-title":"Management of patients with Alzheimer\u2019s disease plus cerebrovascular disease: 12-month treatment with galantamine","volume":"17","author":"Bullock","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2023112303242872800_ref63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(08)70261-8","article-title":"Safety and efficacy of galantamine (Reminyl) in severe Alzheimer\u2019s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial","volume":"8","author":"Burns","year":"2009","journal-title":"Lancet Neurol"},{"key":"2023112303242872800_ref64","author":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C"},{"key":"2023112303242872800_ref65","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"2023112303242872800_ref66","first-page":"391","article-title":"Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer\u2019s disease","volume":"10","author":"Hager","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2023112303242872800_ref67","author":"Janssen Pharmaceutical K.K"},{"key":"2023112303242872800_ref68","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"2023112303242872800_ref69","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer\u2019s disease: multicentre randomised controlled trial","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"key":"2023112303242872800_ref70","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"2023112303242872800_ref71","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/gps.409","article-title":"Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer\u2019s disease","volume":"16","author":"Wilkinson","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"2023112303242872800_ref72","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1212\/01.wnl.0000303815.69777.26","article-title":"Safety and efficacy of galantamine in subjects with mild cognitive impairment","volume":"70","author":"Winblad","year":"2008","journal-title":"Neurology"},{"key":"2023112303242872800_ref73"},{"key":"2023112303242872800_ref74","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1185\/03007990802328142","article-title":"Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study","volume":"24","author":"Ballard","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2023112303242872800_ref75","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/mds.21997","article-title":"Rivastigmine versus placebo in hyperhomocysteinemic Parkinson\u2019s disease dementia patients","volume":"23","author":"Barone","year":"2008","journal-title":"Mov Disord"},{"key":"2023112303242872800_ref76","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1089\/neu.2020.7146","article-title":"Rivastigmine transdermal patch treatment for moderate to severe cognitive impairment in veterans with traumatic brain injury (RiVET study): a randomized clinical trial","volume":"38","author":"Brawman-Mintzer","year":"2021","journal-title":"J Neurotrauma"},{"key":"2023112303242872800_ref77","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson\u2019s disease","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"key":"2023112303242872800_ref78","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000438824","article-title":"Impact of rivastigmine on cognitive dysfunction and falling in Parkinson\u2019s disease patients","volume":"74","author":"Li","year":"2015","journal-title":"Eur Neurol"},{"key":"2023112303242872800_ref79","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0404.2009.01263.x","article-title":"A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease","volume":"121","author":"Narasimhalu","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"2023112303242872800_ref80","author":"Novartis Pharmaceuticals"},{"key":"2023112303242872800_ref81","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/02699050902926275","article-title":"A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injury\u2014what it showed and taught?","volume":"23","author":"Tenovuo","year":"2009","journal-title":"Brain Inj"},{"key":"2023112303242872800_ref82","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/gps.1788","article-title":"A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer\u2019s disease\u2013\u2013rivastigmine patch versus capsule","volume":"22","author":"Winblad","year":"2007","journal-title":"Int J Geriatr Psychiatry"},{"key":"2023112303242872800_ref83","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins"},{"key":"2023112303242872800_ref84","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006104","article-title":"Donepezil for mild cognitive impairment","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2023112303242872800_ref85","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"N Engl J Med"},{"key":"2023112303242872800_ref86","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/joim.13244","article-title":"Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer\u2019s disease (MCI and dementia) in primary care: a review and synthesis","volume":"290","author":"Liss","year":"2021","journal-title":"J Intern Med"},{"key":"2023112303242872800_ref87","first-page":"CD009132","article-title":"Cholinesterase inhibitors for mild cognitive impairment","volume":"2012","author":"Russ","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2023112303242872800_ref88","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1136\/jnnp.74.9.1294","article-title":"Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension","volume":"74","author":"Singer","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023112303242872800_ref89","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1177\/1533317516666195","article-title":"Effects of acetylcholinesterase inhibitors on balance and gait functions and orthostatic hypotension in elderly patients with Alzheimer disease","volume":"31","author":"Isik","year":"2016","journal-title":"Am J Alzheimers Dis Dement"},{"key":"2023112303242872800_ref90","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1532-5415.2009.02712.x","article-title":"Galantamine does not cause aggravated orthostatic hypotension in people with Alzheimer\u2019s disease","volume":"58","author":"Beek","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"2023112303242872800_ref91","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5694\/mja2.50015","article-title":"Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary","volume":"210","author":"Reeve","year":"2019","journal-title":"Med J Aust"},{"key":"2023112303242872800_ref92"},{"key":"2023112303242872800_ref93","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.maturitas.2013.02.009","article-title":"Risk factors for falls among older adults: a review of the literature","volume":"75","author":"Ambrose","year":"2013","journal-title":"Maturitas"},{"key":"2023112303242872800_ref94","doi-asserted-by":"crossref","first-page":"e035978","DOI":"10.1136\/bmjopen-2019-035978","article-title":"Deprescribing fall-risk increasing drugs (FRIDs) for the prevention of falls and fall-related complications: a systematic review and meta-analysis","volume":"11","author":"Lee","year":"2021","journal-title":"BMJ Open"},{"key":"2023112303242872800_ref95","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1471-2377-13-188","article-title":"The ReSPonD trial \u2013 rivastigmine to stabilise gait in Parkinson\u2019s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson\u2019s disease who have fallen","volume":"13","author":"Henderson","year":"2013","journal-title":"BMC Neurol"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/52\/11\/afad205\/53668762\/afad205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/52\/11\/afad205\/53668762\/afad205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T03:33:55Z","timestamp":1700710435000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ageing\/article\/doi\/10.1093\/ageing\/afad205\/7425521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":95,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afad205","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"value":"0002-0729","type":"print"},{"value":"1468-2834","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,2]]},"published":{"date-parts":[[2023,11,2]]},"article-number":"afad205"}}